Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
- Previous Close
0.158 - Open
0.158 - Bid 0.153 x --
- Ask 0.156 x --
- Day's Range
0.151 - 0.167 - 52 Week Range
0.121 - 0.380 - Volume
1,640,000 - Avg. Volume
2,265,192 - Market Cap (intraday)
256.734M - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
7.65 - EPS (TTM)
0.020 - Earnings Date Mar 25, 2025 - Mar 31, 2025
- Forward Dividend & Yield 0.01 (3.40%)
- Ex-Dividend Date May 15, 2025
- 1y Target Est
--
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, and selling of medicines and medical devices in the People's Republic of China. The company offers medicines for various therapeutic areas, including oncology, cardiovascular system, respiratory system, digestive system, and mental disorders. It also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology business. Shenzhen Neptunus Interlong Bio-technique Company Limited was incorporated in 2002 and is based in Quarry Bay, Hong Kong. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
www.interlong.com1,485
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 8329.HK
View MorePerformance Overview: 8329.HK
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 8329.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 8329.HK
View MoreValuation Measures
Market Cap
265.12M
Enterprise Value
72.39M
Trailing P/E
9.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.24
Price/Book (mrq)
0.26
Enterprise Value/Revenue
0.06
Enterprise Value/EBITDA
0.96
Financial Highlights
Profitability and Income Statement
Profit Margin
2.40%
Return on Assets (ttm)
1.54%
Return on Equity (ttm)
1.35%
Revenue (ttm)
1.04B
Net Income Avi to Common (ttm)
25.01M
Diluted EPS (ttm)
0.020
Balance Sheet and Cash Flow
Total Cash (mrq)
283.42M
Total Debt/Equity (mrq)
10.27%
Levered Free Cash Flow (ttm)
3.7M